Plasminogen activator inhibitor type I (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines

European Journal of Clinical Investigation

Volumn 35, Issue 9, 2005, Pages 583-590

  He, G ^a,c   Andersen, O ^b   Haugaard, S B ^b   Lihn, A S ^b,c   Pedersen, S B ^a,c   Madsbad, S ^b   Richelsen, Bjørn ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Adipose tissue; Cytokines; Human immunodeficiency virus (HIV); Insulin resistance; Lipodystrophy; Plasminogen activator inhibitor type 1 (PAI 1)

Indexed keywords

ADIPOCYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRY; ARTICLE; BODY FAT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADIPOSE TISSUE; ADULT; BODY MASS INDEX; CYTOKINES; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24144431592     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01547.x     Document Type: Article

References (45)

1. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000;85:35-41.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
3. Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS 2001;15:1917-30.
4. Fogh-Andersen N, D'Orazio P. Proposal for standardizing direct-reading biosensors for blood glucose. Clin Chem 1998;44:655-9.
5. Hirsch HH, Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection 2002;30:293-8.
6. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 2001;12:413-9.
7. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1 infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:441-9.
8. Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. J Thromb Haemost 1993;70:138-43.
9. Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. J Thromb Haemost 1995;74: 71-6.
10. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-801.
11. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-7.
12. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998;22:312-7.
13. Giltay EJ, Elbers JM, Gooren LJ, Emeis JJ, Kooistra T, Asscheman H et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998;18:1716-22.
14. Mertens I, Van der Planken M, Corthouts B, Wauters M, Peiffer F, De Leeuw I, Van Gaal L et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001;33:602-7.
15. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-43.
16. Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G, Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol 1999;19:1361-5.
17. Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003;23:688-94.
18. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
19. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6. Depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-50.
20. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol 1997;54:801-8.
21. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
22. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
23. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian S et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis 1999;143:81-90.
24. He G, Pedersen SB, Bruun JM, Richelsen B. Regulation of plasminogen activator inhibitor-1 in human adipose tissue: interaction between cytokines, cortisol and estrogen. Horm Metab Res 2000;32:515-20.
25. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999;96:6902-7.
26. Fernadez-real J, Broch M, Ricart W, Casamitjana R, Gutierrez C, Vendrell J et al. Plasma level of the soluble fraction of tumor nucrosis factor receptor 2 and insulin resistance. Diabetes 2003;47:1757-62.
27. Hauner H, Bender M, Haastert B, Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord 1998;22:1239-43.
28. Pandey M, Tuncman G, Hotamisligil GS, Samad F. Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. Am J Pathol 2003;162:933-41.
29. Pedersen SB, Børglum J, Jørgensen J, Richelsen B. Growth hormone treatment of obese premenopausal women: effects on isolated adipocyte metabolism. Endocrinol and Metabolism 1995;2:251-8.
30. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
31. Buhl ES, Jessen N, Schmitz O, Pedersen SB, Pedersen O, Holman GD et al. Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. Diabetes 2001;50:12-7.
32. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999;22 (Suppl. 3):C25-30.
33. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001;60:349-56.
34. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000;20:1682-7.
35. Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism 2000;49:666-71.
36. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-8.
37. Kotler DP, Ionescu G, Johnson JA, Inada Y, He Q, Engelson ES et al. Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy. Clin Infect Dis 2003;37 (Suppl. 2):S47-51.
38. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-21.
39. Bastelica D, Mavri A, Verdierl M, Berthet B, Juhan-Vague I, Alessi MC. Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNF-alpha receptors to PAI-1 levels. Thromb Haemost 2002;88:481-7.
40. Mondal D, Larussa VF, Agrawal KC. Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. AIDS Res Hum Retroviruses 2001;17:1569-84.
41. Bastelica D, Morange P, Berthet B, Borghi H, Lacroix O, Grino M et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002;22:173-8.
42. He G, Pedersen SB, Bruun JM, Lihn AS, Jensen PF, Richelsen B. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res 2003;35:178-82.
43. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285:E1072-80.
44. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003;88:627-36.
45. He G, Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro. Biochem Biophys Res Commun 2003;310:878-83.